Abcam plc
2023
$5.7B
Why
Acquired Cambridge-based life science reagents provider, adding proprietary recombinant monoclonal antibodies, binders, and assays used in proteomic research.
Danaher
Life Sciences Tools & DiagnosticsFounded 1984- HQ today: Washington, District of Columbia, United States
Reviewed by Swet Parvadiya
Company data updated: February 2025
Acquisitions
Danaher Acquisitions
7
Major Deals Covered
$63.3B
Disclosed Deal Value
What are Danaher's biggest acquisitions?
Danaher's largest disclosed acquisition here is Cytiva (GE Biopharma) for $21.4 in 2020. This page covers 7 major deals from 2011 to 2023, each with its price where disclosed and the reason behind it.
- Major deals covered
- 7
- Largest deal
- Cytiva (GE Biopharma) ($21.4)
- First deal
- 2011
- Most recent
- 2023
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2020 | Undisclosed | — | |
| 2015 | Undisclosed | — | |
| 2021 | Undisclosed | — | |
| 2011 | Undisclosed | — | |
| 2023 | Undisclosed | — | |
| 2016 | Undisclosed | — | |
| 2018 | Undisclosed | — |
- What companies has Danaher bought?
- Major acquisitions by Danaher documented here include Cytiva (GE Biopharma) (2020), Pall Corporation (2015), Aldevron (2021), Beckman Coulter (2011) and Abcam plc (2023).
- What is Danaher's most recent acquisition?
- The most recent Danaher acquisition documented here is Abcam plc, in 2023, for $5.7.
Aldevron
2021
$9.6B
Why
Acquired foundational producer of cGMP plasmid DNA, recombinant proteins, and mRNA raw materials supporting cell and gene therapies and novel genetic vaccines.
Cytiva (GE Biopharma)
2020
$21.4B
Why
Acquired General Electric's biopharma business to create Cytiva, securing market-leading chromatography resins, single-use bioreactors, and filtration systems used in over 70% of global biologic drugs.
Integrated DNA Technologies (IDT)
2018
$2.0B
Why
Acquired custom synthetic DNA and RNA manufacturer, providing essential reagents for genomics, next-generation sequencing target enrichment, and CRISPR editing.
Cepheid
2016
$4.0B
Why
Acquired rapid molecular diagnostic pioneer, bringing the GeneXpert automated testing platform which became a vital frontline asset during global respiratory testing.
Pall Corporation
2015
$13.8B
Why
Acquired global leader in advanced filtration, separation, and purification systems for biotechnology, pharmaceuticals, aerospace, and industrial processing.
Beckman Coulter
2011
$6.8B
Why
Acquired biomedical testing leader, establishing Danaher's clinical diagnostics flagship across clinical chemistry, hematology, and immunoassay laboratory automation.
Danaher's Growth & Acquisition Strategy
Danaher's growth strategy centers on three self-reinforcing mechanisms: organic innovation via focused R&D, commercial DBS execution, and disciplined strategic M&A. Organically, Danaher reinvests roughly 6.6% of sales ($1.58 billion in FY2024) into engineering next-generation chromatography media, high-throughput diagnostic systems, and automated single-use fluid handling technologies. Commercially, Danaher applies DBS Growth Tools—including Voice of the Customer (VOC), Growth Accelerator, and Digital Marketing Kaizens—to increase cartridge and consumable attach rates across its global installed base. Strategically, Danaher exercises disciplined capital deployment, targeting category leaders with proprietary technology, high consumable intensity, and significant opportunity for margin expansion under DBS governance.
How Danaher Makes Money
Danaher's business model is engineered around a high-margin 'razor-and-blade' economic architecture supercharged by the Danaher Business System (DBS). The company develops, manufactures, and places highly sophisticated scientific instruments—such as Cepheid GeneXpert molecular diagnostic systems, Beckman Coulter clinical laboratory analyzers, Cytiva AKTA chromatography systems, and Leica confocal microscopes—into pharmaceutical companies, contract development and manufacturing organizations (CDMOs), academic research laboratories, and hospital networks. Once an instrument is validated and integrated into customer workflows and regulatory filings (such as FDA Biologics License Applications), it creates an annuity stream of proprietary, high-margin consumable sales, reagents, assays, and long-term service contracts that generate more than 80% of total company revenue. Capital allocation serves as the primary compounding engine. Danaher utilizes its robust free cash flow conversion—typically exceeding 100% of net income—to reinvest in disciplined organic R&D (~6.6% of sales) while accumulating dry powder for programmatic acquisitions. By acquiring established scientific leaders with leading technology but sub-optimal operational efficiency, Danaher applies DBS tools (Visual Management, Kaizen, Value Stream Mapping, and Strategic Policy Deployment) to expand operating margins by 300 to 700 basis points within three to five years post-acquisition. Danaher maintains relentless price discipline and working capital management, turning inventory faster and keeping Days Sales Outstanding (DSO) low, ensuring superior returns on invested capital (ROIC) across macro cycles.
Danaher Acquisitions FAQ
What was Danaher's largest acquisition in company history?
Danaher's largest acquisition was GE Biopharma, purchased from General Electric for $21.4 billion in March 2020 and subsequently rebranded as Cytiva.
How does Danaher integrate acquired companies so effectively?
Danaher deploys the Danaher Business System (DBS), embedding continuous improvement facilitators to redesign plant workflows, optimize pricing, and streamline supply chains.
What companies were spun off from Danaher Corporation?
Danaher spun off Fortive Corporation in 2016 (industrial technologies), Envista Holdings in 2019 (dental products), and Veralto Corporation in 2023 (water and environmental technologies).
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Danaher
Core profile pages, founders and related research hubs for this company.